QPPV.COM KNOWLEDGE ASSESSMENT

Tezepelumab: TSLP Biology, Severe Asthma, CRSwNP and Product Pharmacovigilance

Test your understanding of the concepts covered by Tezepelumab: TSLP Biology, Severe Asthma, CRSwNP and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which report would provide the strongest basis for investigating a potential new infection signal rather than an isolated background event?

One uncomplicated common respiratory infection with no additional information A pattern of unusual, severe or recurrent infections with coherent timing across cases and limited alternative explanations A single report of transient injection-site redness A report of improved asthma control after treatment

Question 2 of 10 Why should a rash or dyspnoea reported after injection not automatically be coded as hypersensitivity?

Temporal association can never be relevant for monoclonal antibodies Similar symptoms may result from injection-site reactions, asthma, viral infection or other causes, so the clinical syndrome must be reconstructed Hypersensitivity is possible only after the first dose All respiratory symptoms after biologic administration represent lack of efficacy

Question 3 of 10 Why is TSLP considered an upstream target in airway inflammation?

It is released early by stressed epithelial cells and can influence several downstream immune pathways It is produced only after eosinophils have completed their inflammatory activity It directly contracts bronchial smooth muscle before any immune response occurs It is the final common mediator of every form of asthma

Question 4 of 10 Which statement best describes the significance of EU additional-monitoring status for Tezspire?

It proves that the medicine has an unacceptable safety profile It is a regulatory mechanism intended to support rapid identification of new safety information It means only serious reactions should be reported It replaces the need to consult current product information

Question 5 of 10 Which patient most closely reflects the EU severe-asthma population described in the article?

An adult with occasional mild wheeze controlled by a short-acting bronchodilator alone A 14-year-old whose severe asthma remains inadequately controlled despite high-dose inhaled corticosteroids plus another maintenance medicine An adult with an isolated acute asthma attack who has never used controller therapy A child younger than 12 years with seasonal rhinitis but no asthma

Question 6 of 10 A patient improves on tezepelumab, undergoes a rapid oral corticosteroid taper, and then develops fatigue, wheeze and eosinophilia. What causal model should be prioritised for investigation?

The symptoms must represent direct tezepelumab toxicity Corticosteroid withdrawal or loss of corticosteroid suppression may explain the event and should be evaluated alongside disease activity and infection The event cannot be relevant to pharmacovigilance because it followed clinical improvement The event proves that tezepelumab has failed pharmacologically

Question 7 of 10 Which description best reflects the article's EU positioning of tezepelumab for severe CRSwNP?

Monotherapy for all forms of uncomplicated rhinitis Add-on therapy with intranasal corticosteroids for adults with severe CRSwNP inadequately controlled by systemic corticosteroids and/or surgery Acute treatment for bacterial sinusitis in children Replacement therapy for surgical management in every patient with nasal polyps

Question 8 of 10 Which approach best reflects mechanism-informed assessment of an infection report during tezepelumab treatment?

Assume every infection is caused by immune suppression Dismiss all infections because TSLP blockade is not complete immune suppression Assess infection type, pathogen, severity, recurrence, corticosteroid and other immunosuppressive exposure, comorbidities and chronology Consider only whether the infection occurred within 24 hours of injection

Question 9 of 10 A caregiver reports liquid on the skin after using a pre-filled pen, followed by worsening asthma. What should be separated first in the assessment?

Product quality, administration technique, completeness of the dose and subsequent disease worsening Only whether the patient had high baseline eosinophils Only whether the caregiver considers the product ineffective Hypersensitivity and infection, without assessing the injection itself

Question 10 of 10 What is the most accurate interpretation of tezepelumab efficacy across baseline blood eosinophil strata?

Low eosinophils prove that no biomarker is clinically informative Benefit across eosinophil strata supports upstream targeting, while other biomarkers and phenotype may still inform response and treatment choice Only patients with high eosinophils can respond to TSLP blockade Eosinophil measurements establish individual causality for adverse events

Tezepelumab: TSLP Biology, Severe Asthma, CRSwNP and Product Pharmacovigilance

Cookie Settings